Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Budesonide suppositories plus oral mesalazine versus oral mesalazine alone in acute ulcerative colitis
2019-003334-16Phase 3Completed
- Sponsor
- Dr. Falk Pharma GmbH
- Start
- May 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Budenofalk + Salofalk with Placebo suppository + Salofalk (2 arms). Primary endpoint: Co-primary efficacy endpoints. Started May 2020; status: completed.
02
Drugs
budesonideSalcrozine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2019-003334-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003334-16.